| answer text |
<p>Part IX will remain a list of devices available to be prescribed in the community,
via the FP10 prescription route. The Department believes that it is currently difficult
to identify which devices are broadly comparable, and whether more expensive devices
provide added value. The proposed amendments that were consulted on were intended
to increase meaningful choice, not to decrease the choice for clinicians and patients.
Comparison between products can increase awareness of different brands amongst prescribers,
which can support small and medium sized businesses in entering the market.</p><p>The
consultation response on the proposed amendments to Part IX is expected to be released
in May 2024, which will outline the Government’s response. Any amendments that are
taken forward will happen gradually, with review points and engagement with stakeholders,
including industry, patient representatives, clinicians, and National Health Service
organisations. We are aware that there are some very good devices in use, relied upon
by clinicians and patients.</p>
|
|
